MNKD Mannkind Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: MNKD

Price (delayed)

$3.355

Market cap

$1.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.07

Enterprise value

$1.55B

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 25
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 32

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its ...

Highlights
Mannkind's gross profit has increased by 23% YoY and by 4.5% from the previous quarter
The revenue has grown by 21% YoY and by 3.4% from the previous quarter
The company's debt has surged by 97% YoY but it fell by 6% QoQ
Mannkind's net income has plunged by 179% YoY
Mannkind's EPS has plunged by 170% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.mannkindcorp.com/
Peers: HALO NKTR LLY PFE

Key stats

What are the main financial stats of MNKD

MNKD stock price

How has the Mannkind stock price performed over time
Intraday
-0.15%
1 week
-7.83%
1 month
19.4%
1 year
-22.87%
YTD
-40.83%
QTD
36.94%

Financial performance

How have Mannkind's revenue and profit performed over time
Revenue
$360.78M
Gross profit
$272.87M
Operating income
$18.76M
Net income
-$23.91M
Gross margin
75.6%
Net margin
-6.6%
Mannkind's net income has plunged by 179% YoY
The company's net margin has shrunk by 165% YoY
MNKD's operating margin has dropped by 80% year-on-year and by 61% since the previous quarter
MNKD's operating income has shrunk by 76% YoY and by 60% QoQ

Price vs fundamentals

How does MNKD's price correlate with its fundamentals

Growth

What is Mannkind's growth rate over time

Valuation

What is Mannkind stock price valuation
MNKD P/E details
P/E
N/A
P/B
N/A
P/S
2.87
EV/EBIT
137.87
EV/EBITDA
53.48
EV/Sales
4.3
Mannkind's EPS has plunged by 170% YoY
The equity has declined by 16% since the previous quarter
The P/S is 66% lower than the 5-year quarterly average of 8.5 and 28% lower than the last 4 quarters average of 4.0
The revenue has grown by 21% YoY and by 3.4% from the previous quarter

Efficiency

How efficient is Mannkind business performance
The ROA has shrunk by 156% YoY
Mannkind's ROS has plunged by 87% YoY and by 73% from the previous quarter
The company's return on invested capital has shrunk by 85% YoY and by 74% QoQ

Dividends

What is MNKD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNKD.

Financial health

How did Mannkind financials performed over time
The company's total assets is 7% lower than its total liabilities
The company's total assets has surged by 81% YoY but it fell by 6% QoQ
MNKD's total liabilities has surged by 71% year-on-year but it is down by 4.7% since the previous quarter
The company's debt has surged by 97% YoY but it fell by 6% QoQ
The debt to equity has dropped by 95% year-on-year but it is up by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.